Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

Automated summary

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 0.4% required hospitalization by day 30. Rebound of symptoms occurred in 0.8% of patients at a median of 9 days after treatment, but all resolved without additional COVID-19-directed therapy.